Anti-transforming Growth Factor (TGF)-beta Antibodies Inhibit Breast Cancer Cell Tumorigenicity and Increase Mouse Spleen Natural Killer Cell Activity. Implications for a Possible Role of Tumor Cell/host TGF-beta Interactions in Human Breast Cancer...

Overview

Journal J Clin Invest

Specialty General Medicine

Date 1993 Dec 1

PMID 7504687

Citations 100

Authors

C L Arteaga

S D Hurd

A R Winnier

M D Johnson

B M Fendly

J T Forbes

Affiliations

Soon will be listed here.

Abstract

TGF-beta effects on angiogenesis, stroma formation, and immune function suggest its possible involvement in tumor progression. This hypothesis was tested using the 2G7 IgG2b, which neutralizes TGF-beta 1, -beta 2, and -beta 3, and the MDA-231 human breast cancer cell line. Inoculation of these cells in athymic mice decreases mouse spleen natural killer (NK) cell activity. Intraperitoneal injections of 2G7 starting 1 d after intraperitoneal inoculation of tumor cells suppressed intraabdominal tumor and lung metastases, whereas the nonneutralizing anti-TGF-beta 12H5 IgG2a had no effect. 2G7 transiently inhibited growth of established MDA-231 subcutaneous tumors. Histologically, both 2G7-treated and control tumors were identical. Intraperitoneal administration of 2G7 resulted in a marked increase in mouse spleen NK cell activity. 2G7 did not inhibit MDA-231 primary tumor or metastases formation, nor did it stimulate NK cell-mediated cytotoxicity in beige NK-deficient nude mice. Finally, serum-free conditioned medium from MDA-231 cells inhibited the NK cell activity of human blood lymphocytes. This inhibition was blocked by the neutralizing anti-TGF-beta 2G7 antibody but not by a nonspecific IgG2. These data support a possible role for tumor cell TGF-beta in the progression of mammary carcinomas by suppressing host immune surveillance.

Citing Articles

Exploring TGF-β Signaling in Cancer Progression: Prospects and Therapeutic Strategies.

Sheikh K, Amjad M, Irfan M, Anjum S, Majeed T, Riaz M Onco Targets Ther. 2025; 18:233-262.

PMID: 39989503 PMC: 11846535. DOI: 10.2147/OTT.S493643.

Siglec15/TGF-β bispecific antibody mediates synergistic anti-tumor response against 4T1 triple negative breast cancer in mice.

Shen L, Schaefer A, Tiruthani K, Wolf W, Lai S Bioeng Transl Med. 2024; 9(5):e10651.

PMID: 39553435 PMC: 11561775. DOI: 10.1002/btm2.10651.

TGF-β signaling in health, disease, and therapeutics.

Deng Z, Fan T, Xiao C, Tian H, Zheng Y, Li C Signal Transduct Target Ther. 2024; 9(1):61.

PMID: 38514615 PMC: 10958066. DOI: 10.1038/s41392-024-01764-w.

Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.

Liu S, Xie S, Liu W, Gagea M, Hanker A, Nguyen N Res Sq. 2023; .

PMID: 36824840 PMC: 9949251. DOI: 10.21203/rs.3.rs-2388864/v1.

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy.

Yi M, Li T, Niu M, Wu Y, Zhao Z, Wu K Front Immunol. 2023; 13:1061394.

PMID: 36601124 PMC: 9807229. DOI: 10.3389/fimmu.2022.1061394.

References

Laiho M, Keski-Oja J . Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res. 1989; 49(10):2533-53. View

Zajchowski D, Band V, Pauzie N, Tager A, Stampfer M, Sager R . Expression of growth factors and oncogenes in normal and tumor-derived human mammary epithelial cells. Cancer Res. 1988; 48(24 Pt 1):7041-7. View

Arrick B, Korc M, Derynck R . Differential regulation of expression of three transforming growth factor beta species in human breast cancer cell lines by estradiol. Cancer Res. 1990; 50(2):299-303. View

Torre-Amione G, Beauchamp R, Koeppen H, Park B, Schreiber H, Moses H . A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci U S A. 1990; 87(4):1486-90. PMC: 53500. DOI: 10.1073/pnas.87.4.1486. View

King R, Wang D, Daly R, Darbre P . Approaches to studying the role of growth factors in the progression of breast tumours from the steroid sensitive to insensitive state. J Steroid Biochem. 1989; 34(1-6):133-8. DOI: 10.1016/0022-4731(89)90073-3. View

Barrett-Lee P, Travers M, Luqmani Y, Coombes R . Transcripts for transforming growth factors in human breast cancer: clinical correlates. Br J Cancer. 1990; 61(4):612-7. PMC: 1971371. DOI: 10.1038/bjc.1990.136. View

Daly R, King R, Darbre P . Interaction of growth factors during progression towards steroid independence in T-47-D human breast cancer cells. J Cell Biochem. 1990; 43(3):199-211. DOI: 10.1002/jcb.240430302. View

Lucas C, Bald L, Fendly B, Figari I, Patzer E, Palladino M . The autocrine production of transforming growth factor-beta 1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA. J Immunol. 1990; 145(5):1415-22. View

Welch D, Fabra A, Nakajima M . Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci U S A. 1990; 87(19):7678-82. PMC: 54811. DOI: 10.1073/pnas.87.19.7678. View

10.

Wallick S, Figari I, Morris R, Levinson A, Palladino M . Immunoregulatory role of transforming growth factor beta (TGF-beta) in development of killer cells: comparison of active and latent TGF-beta 1. J Exp Med. 1990; 172(6):1777-84. PMC: 2188774. DOI: 10.1084/jem.172.6.1777. View

11.

Arteaga C, Coffey Jr R, Dugger T, McCutchen C, Moses H, Lyons R . Growth stimulation of human breast cancer cells with anti-transforming growth factor beta antibodies: evidence for negative autocrine regulation by transforming growth factor beta. Cell Growth Differ. 1990; 1(8):367-74. View

12.

Zugmaier G, Paik S, Wilding G, Knabbe C, Bano M, Lupu R . Transforming growth factor beta 1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. Cancer Res. 1991; 51(13):3590-4. View

13.

Wu S, Theodorescu D, Kerbel R, WILLSON J, Mulder K, Humphrey L . TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol. 1992; 116(1):187-96. PMC: 2289262. DOI: 10.1083/jcb.116.1.187. View

14.

Steiner M, Barrack E . Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol. 1992; 6(1):15-25. DOI: 10.1210/mend.6.1.1738367. View

15.

Walker R, Dearing S . Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer. 1992; 28(2-3):641-4. DOI: 10.1016/s0959-8049(05)80116-9. View

16.

Arrick B, Lopez A, Elfman F, Ebner R, Damsky C, Derynck R . Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor beta 1. J Cell Biol. 1992; 118(3):715-26. PMC: 2289543. DOI: 10.1083/jcb.118.3.715. View

17.

Arteaga C, Moses H, Hurd S, Pietenpol J . Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ. 1993; 4(3):193-201. View

18.

Sehested M, HOU-JENSEN K . Factor VII related antigen as an endothelial cell marker in benign and malignant diseases. Virchows Arch A Pathol Anat Histol. 1981; 391(2):217-25. DOI: 10.1007/BF00437598. View

19.

Moses H, Branum E, Proper J, Robinson R . Transforming growth factor production by chemically transformed cells. Cancer Res. 1981; 41(7):2842-8. View

20.

Roberts A, Anzano M, Lamb L, Smith J, Sporn M . New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci U S A. 1981; 78(9):5339-43. PMC: 348740. DOI: 10.1073/pnas.78.9.5339. View